Год: 2016
Язык: Russian
Этот материал также есть на других языках: Арабский Английский Французский Испанский Китайский (упрощенный)
Автор(ы): World Federation of Hemophilia
Формат: Документ
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).
A summary of discussions held at the Eleventh WFH Global Forum on Research and Treatment Products for Bleeding Disorders which
This module was presented by Susan Cutter at the Virtual Workshop for Psychosocial Professionals in Europe on June 23, 2021.
Listen to this 2-hour webinar presented on April 22, 2021 to learn about global topics related to bleeding disorders. The
This illustrated schematic demonstrates the normal process of blood clotting, how it is diminished when a clotting factor is lacking,
Also Available In: Japanese A national tender system is a cost-effective system for the purchase of products or services, such
Also Available In: Japanese Access to home treatment reduces the economic impact on healthcare systems and improves the quality of
© 2025 World Federation of Hemophilia
